No class action over Baycol in the US
The Federal District Court in Minneapolis, Minnesota, has found in favour of Bayer and denied a motion to certify a nationwide class action in the Baycol litigation.
The Federal District Court in Minneapolis, Minnesota, has found in favour of Bayer and denied a motion to certify a nationwide class action in the Baycol litigation.
Bayer argued that certification of a class action was not appropriate because the claims of the possible class members involve too many diverse and individual issues. Some of these include differences in state law, medical histories, Baycol dosages and Baycol use with other drugs. In addition, Bayer believes that a class action would have proven to be unmanageable.
The company says it will continue its strategy of analysing the specific circumstances of each case and the nature of each claim. It will also continue to pursue its policy of trying to agree on fair compensation for anyone who experienced serious side effects from Baycol on its own initiative and without acknowledging any legal liability. Bayer has successfully settled 1,342 cases in the US to date.